Results 61 to 70 of about 26,143 (169)
Zhongguo shiyan zhenduanxue, 2017 胃癌是胃粘膜上皮的恶性肿瘤,其发病率和死亡率都位于第三位的恶性肿瘤。而且胃癌的发病年龄无局限性,胃癌的发病年龄常见于40-60岁[1]。现阶段胃癌的治疗方法主要是手术切除,之后化疗辅助治疗。顺铂为传统化疗药物,其与DNA交联诱导双链断裂而引起损伤,发挥其毒性作用,应用在胃癌化疗的不同时段,如辅助化疗的ECF方案,姑息化疗的DCF方案和分子靶向治疗的PF ...
张鑫, 张迪, 饶艳伟, 宋晓斌
doaj
A meta-analysis of Pemetrexed plus Platinum Chemotherapy versus Gemcitabine plus Platinum Chemotherapy for Advanced Non-small Cell Lung Cancer [PDF]
, 2011 Background and objective Whether pemetrexed plus platinum (PP) regimen is superior to gemcitabine plus platinum (GP) regimen for patients with advanced non-small cell lung cancer (NSCLC) is unclear.
Jin JIANG +5 more
core
Immediate Versus Delayed Topotecan after First-line Therapy in Small Cell Lung Cancer [PDF]
, 2010 Background and objective How to prolong progression free survival (PFS) and overall survival (OS) of patients with small cell lung cancer (SCLC) has been one of the hottest issues. We retrospectively reviewed our data to compare the survival of immediate
Cong XUE +7 more
core
Zhongshan Daxue xuebao. Yixue kexue ban, 2014 【目的】 初步评价肝动脉灌注化疗联合局部内生场热疗（热化疗）在肝门部胆管癌治疗的临床应用价值。【方法】对２００３年１０月至２０１３年６月期间３９例接受介入治疗的肝门部胆管癌病人进行回顾性研究，其中热化疗组２０例，于肝动脉置管，灌注吉西他滨后，再行肝动脉持续灌注卡铂及肿瘤区域内生场热疗６０ｍｉｎ，热化疗后连续肝动脉灌注５－Ｆｕ ３ ｄ，第８天静脉应用吉西他滨１次。对照组１９例，肝动脉置管及化疗方案同前，未行热疗。上述治疗每４周为１疗程。化疗期间观察化疗毒副反应、并发症及耐受性 ...
doaj
Zhongguo shiyan zhenduanxue, 2017 目的探讨血清中miR-19b,miR-125b,miR-34a,miR-200b的表达与非小细胞肺癌发生发展的相关性,以及这4种microRNAs在化疗过程中表达水平的变化和对患者化疗的监测效果。方法采用实时荧光定量PCR（Real-time PCR）技术检测43例健康体检者和非小细胞肺癌患者血清中miR-19,miR-125b,miR-34a,miR-200b的表达水平,以及化疗过程中的表达变化,比较第二次、第六次化疗后microRNAs的表达差异。结果与健康对照组相比,非小细胞肺癌患者血清中miR ...
王丹丹, 刘牟林, 李士军
doaj
Survival Analysis of 1,742 Patients with Stage IV Non-small Cell Lung Cancer [PDF]
, 2011 Background and objective At present non-small cell lung cancer (NSCLC) is still the leading cause of death induced by cancer. The aim of this study is to investigate the prognostic factors of advanced NSCLC.
Baohui HAN, Hong PENG, Meili MA
core
The Analysis of Erlotinib on Brain Metastases in Patients with Non-small-cell Lung Cancer [PDF]
, 2009 Background and objective Brain metastases are common in non-small-cell lung cancer (NSCLC) and the prognosis is poor. Erlotinib is a specific inhibitor of the epidermal growth factor receptor-associated tyrosine kinase (EGFRTKI), which has been gradually
Baohui HAN, Hao BAI
core
鲑鱼降钙素联合氯化锶对恶性肿瘤骨转移性骨痛及对血锶代谢影响的临床观察
Zhongguo shiyan zhenduanxue, 2016 目的观察降钙素联合氯化89鍶治疗恶性肿瘤骨转移痛的疗效,判断降钙素在治疗中的作用。方法 73名恶性肿瘤骨转移病例分为,联合组29例患者,用氯化89鍶（3-4mci iv）+降钙素（100IU喷鼻1次/天）;氯化89鍶治疗组25例患者,用氯化89鍶（3-4mci iv）和对照组19例患者,不同意锶治疗的肿瘤骨转移病人（其它方法治疗骨痛）,观察镇痛总有效率并以火焰原子吸收法测定全血鍶含量,随诊12个月,2例死亡退出观察。结果联合治疗组疗效高峰出现在第一个月,总有效率96.4%（27/28 ...
张云平, 李仰康, 刘阳晨
doaj
The Role of Postoperative Radiotherapy on Stage N2 Non-small Cell Lung Cancer [PDF]
, 2009 Background and objective The clinical value of postoperative radiotherapy (PORT) in stage N2 nonsmall-cell lung cancer (NSCLC) is controversy. The aim of this study is to analyze the efficacy of PORT in subgroup of stage N2 NSCLC, which can help ...
Changli WANG +7 more
core
Zhongguo shiyan zhenduanxue, 2009 目的探讨乳腺癌新辅助化疗对血清肝细胞生长因子水平的影响及相关临床意义。方法应用酶链免疫吸附法（ELISA）检测100例可手术乳腺癌患者新辅助化疗前及术后的血清肝细胞因子水平,并评估其水平与乳腺癌新辅助化疗疗效的关系。结果血清肝细胞生长因子水平与乳腺癌的分期密切相关（P=0.018）;血清肝细胞生长因子水平在治疗前后的变化与新辅助化疗效果密切相关。结论血清肝细胞生长因子可能在乳腺癌的发生发展中起重要作用,可能是预测化疗疗效的独立指标。
王承正, 毛书明, 崔树德
doaj